C4 therapeutics reports fourth quarter and full year 2023 financial results and recent business highlights

Cft1946 preclinical data accepted for a poster presentation at the aacr annual meeting 2024 phase 1 dose escalation trials for cft7455 and cft1946 continue to progress; data from both trials expected in 2h 2024 well capitalized with cash runway expected into 2027 watertown, mass., feb. 22, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended december 31, 2023, as well as recent business updates.
CCCC Ratings Summary
CCCC Quant Ranking